NCT02231021 The Practical Evidence of Antidiabetic Combination Therapy in Korea Status COMPLETED Phase PHASE4
NCT02227849 Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Status COMPLETED Phase PHASE4
NCT02227303 A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes Status COMPLETED Phase NA
NCT02226822 DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan Status COMPLETED Phase N/A
NCT02226003 Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) Status COMPLETED Phase PHASE3
NCT02223065 Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State Status COMPLETED Phase PHASE1
NCT02221284 Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)" Status COMPLETED Phase N/A
NCT02220920 Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus Status COMPLETED Phase PHASE4
NCT02220907 Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes Status COMPLETED Phase PHASE3
NCT02220751 Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic Status COMPLETED Phase PHASE3
NCT02212951 Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Status COMPLETED Phase PHASE1/PHASE2
NCT02211261 A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus Status COMPLETED Phase PHASE1
NCT02206607 Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus. Status COMPLETED Phase PHASE1
NCT02201550 Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide Status COMPLETED Phase N/A